Participation in "Kusuri Visionary Meeting 2024"
Aiming for Dialogue and Co-creation Among Diverse Stakeholders
November 27, 2024
Japan Pharmaceutical Manufacturers Association (JPMA) announces its participation in the "Kusuri Visionary Meeting 2024" (hereafter referred to as "the Meeting"), an initiative involving seven organizations and groups* representing patient organizations, government bodies, and other stakeholders**.
The Meeting, proposed by Japan Federation of Cancer Patient Groups, aims to collaborate with a wide range of stakeholders to solve issues related to healthcare and medicines, promote patient involvement, and make a significant impact on society.
Under the theme "Aiming to Improve Access to Drugs," the Meeting was held on November 1, 2024. Participants exchanged opinions on two topics: 1) Patient Involvement in Pharmaceutical Research and Development, and 2) Approach to Providing Information, discussing current activities and challenges.
At the conclusion, it was confirmed that this Meeting should not be a one-time event, and that each stakeholder needs to play their role and cooperate. Finally, as a message to society, all participants agreed to the following:
[Joint Message]
For the Japanese people to lead better lives, it is important to create a place for open dialogue among various stakeholders about issues related to medicine, drugs, etc., and to make efforts to solve them (co-creation), and to continue this effort.
<Summary of Proceedings>
1. Patient Involvement in Pharmaceutical Research and Development
- Understanding and implementation of patient involvement vary among stakeholders, with challenges specific to diseases, fields, and individual stakeholders.
- To resolve issues and promote patient involvement, cross-stakeholder dialogue, information sharing, mutual understanding, and improved literacy are necessary.
- While "patient involvement" is just beginning, the aim is to move towards "public involvement" in the future.
2. Approaches to Information Provision
- In an era where anyone can disseminate and access information through social media, there is a need to create an environment where appropriate information reaches healthcare professionals and patients at the right time.
- Information on stable supply, safety, and clinical trials can be life-critical for patients. It is necessary for all stakeholders, including government, healthcare professionals, patient organizations, and pharmaceutical companies, to collaborate in considering better ways of providing information.
JPMA will continue to work towards resolving issues related to medicines and treatments needed by patients and their families, and realizing a more livable society through co-creation with the stakeholders gathered at this Meeting.
* Seven organizations and groups (in no particular order): Japan Federation of Cancer Patient Groups, Japan Intractable Diseases and Diseases Society, Representative of Self-help Group of Organic Acidemias and Fatty Acid Oxidation Disorders HIDAMARI TANPOPO," Specified NPO ASrid, Ministry of Health, Labour and Welfare, Pharmaceuticals and Medical Devices Agency, JPMA
** Stakeholders: Patient organizations, patients and families, healthcare professionals, academia, government/authorities, pharmaceutical companies, etc.
<Reference: Event Overview>
Date and Time: November 1, 2024 (Friday) 13:15-15:15
Venue: Nihonbashi Life Science Building, 10th Floor Conference Room
Facilitator: Specified NPO ASrid
Organizer: JPMA (Patient Organization Collaboration Promotion Committee)
Discussion Themes: 1) Patient Involvement in Pharmaceutical Research and Development, 2) Approach to Providing Information
[Participants] (In alphabetical order)
Shinsuke Amano (President, Japan Federation of Cancer Patient Groups)
Yasuhiro Fujiwara (Chief Executive, Pharmaceuticals and Medical Devices Agency)
Akiko Kashiwagi (Representative of Self-help Group of Organic Acidemias and Fatty Acid Oxidation Disorders HIDAMARI TANPOPO)
Yukiko Nishimura (President and Founder, Specified NPO ASrid)
Naomi Sakurai (Director, Japan Federation of Cancer Patient Groups)
Kunio Tsuji (Managing Director, Japan Intractable Diseases and Diseases Society)
Hiroyuki Uchiyama (Assistant Vice-Minister for Pharmaceutical Industry Promotion and Medical Information Management, MHLW)
Hiroaki Ueno (President, Japan Pharmaceutical Manufacturers Association)
All conference participants (honorifics omitted)
Back row: Yasuhiro Fujiwara, Shinsuke Amano, Hiroyuki Uchiyama, Kunio Tsuji
Front row: Hiroaki Ueno, Akiko Kashiwagi, Naomi Sakurai, Yukiko Nishimura